Bharat Parenterals' Innoxel Aces EU GMP Audit: Zero Critical Findings!

Audit Triumph

Innoxel Lifesciences, focused on oncology, neurology, and critical care injectables, passed the rigorous EU GMP inspection conducted by Belgium's regulatory body. The Vadodara plant, designed for USFDA, EU GMP, and UK MHRA standards, earned a clean bill with no critical or major issues, following its prior USFDA clearance (one minor Form 483).​

Growth Implications

This milestone accelerates Innoxel's commercial rollout, targeting FY26 revenue of ₹65-70 crore and EBITDA breakeven, with Q1 FY27 CMO supplies. It enhances Bharat Parenterals' portfolio, including Varenyam Healthcare, amid 12-14% standalone growth guidance and EU filings ahead.​

Key Highlights:

Zero Observations: No critical/major findings; full EU GMP compliance confirmed.​

Facility Focus: Liquid injectables/oral liquids for US/EU markets in Vadodara.​

Recent Wins: USFDA EIR post-April 2025 inspection (minor observation closed).​

Pipeline Boost: 20+ products (60% complex ANDAs); 7 new partnerships ($1.85M milestones).​

Outlook: EU supplies H2 FY26; consolidated PAT positive by FY27.​

Sources: Indian Pharma Post, Business Standard, Innoxel Lifesciences, Bharat Parenterals disclosures